The company remains a pre-revenue entity, with R&D expenses consistently consuming the majority of capital, as seen in the $18.0 million R&D spend during 2026Q1.
| Sales/Revenue | -4.85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 128.11M | 0 | 551K | 571K | 1.81M | 685K | 209K | 73K | 44K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -132.96M | 0 | -551K | -571K | -1.81M | -685K | -209K | -73K | -44K |
| Gross Margin % | 2740.82% | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 3.5% | 68.42% | -163.94% | -227.75% | -186.3% | -65.91% | - |
| Operating Expenses | 52.68M | 22.29M | 31.11M | 36.49M | 47.31M | 36.8M | 19.24M | 12.36M | 12.74M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 27.49M | 11.33M | 12.48M | 18.77M | 17.73M | 15.13M | 7.53M | 4.01M | 4.51M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 25.19M | 10.96M | 18.63M | 18.3M | 29.58M | 21.66M | 11.92M | 8.35M | 8.23M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -571K | 0 | 0 | -209K | 0 | 28K |
| Operating Income | -185.64M | -22.29M | -31.66M | -37.06M | -49.12M | -37.48M | -19.45M | -12.44M | -12.74M |
| Operating Margin % | 3826.86% | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 29.61% | 14.57% | 24.54% | -31.05% | -92.7% | -56.42% | 2.39% | - |
| EBITDA | -185.54M | -22.15M | -31.11M | -33.39M | -47.31M | -36.8M | -19.24M | -12.36M | -12.7M |
| EBITDA Margin % | 3824.7% | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -523.46% | 28.81% | 6.81% | 29.43% | -28.58% | -91.23% | -55.65% | 2.63% | - |
| D&A (Non-Cash Add-back) | 105K | 139K | 551K | 3.68M | 1.81M | 685K | 209K | 73K | 44K |
| EBIT | -184.83M | -21.05M | -30.07M | -36.96M | -48.37M | -36.12M | -18.41M | -14.48M | -12.71M |
| Net Interest Income | 814K | 1.21M | 2.46M | 3.48M | 1.56M | 130K | -1.69M | -2.25M | 0 |
| Interest Income | 833K | 1.24M | 2.55M | 3.62M | 1.78M | 800K | 1.69K | 2.26K | 0 |
| Interest Expense | 19K | 32K | 90K | 144K | 219K | 670K | 1.69M | 2.26M | 327K |
| Other Income/Expense | 1.18M | 1.2M | 1.51M | 2.96M | 532K | 688K | -649K | -4.3M | -299K |
| Pretax Income | -184.46M | -21.09M | -30.16M | -34.1M | -48.59M | -36.79M | -20.1M | -16.74M | -13.04M |
| Pretax Margin % | 3802.47% | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -184.46M | -21.09M | -30.16M | -34.1M | -48.59M | -36.79M | -20.1M | -16.74M | -13.04M |
| Net Margin % | 3802.47% | - | - | - | - | - | - | - | - |
| Net Income Growth % | -535.43% | 30.08% | 11.57% | 29.82% | -32.05% | -83.05% | -20.07% | -28.38% | - |
| Net Income (Continuing) | -184.46M | -21.09M | -30.16M | -34.1M | -48.59M | -36.79M | -20.1M | -16.74M | -13.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -142.43 | -16.72 | -1.20 | -1.22 | -1.58 | -1.33 | -0.67 | -0.65 | -19.03 |
| EPS Growth % | -12760.87% | -1293.33% | 1.64% | 22.78% | -18.8% | -98.51% | -3.08% | 96.58% | - |
| EPS (Basic) | - | -16.72 | -1.20 | -1.22 | -1.58 | -1.33 | -0.67 | -0.65 | -19.03 |
| Diluted Shares Outstanding | 1.3M | 1.26M | 25.12M | 27.95M | 30.7M | 27.71M | 30.59M | 29.33M | 685.16K |
| Basic Shares Outstanding | 1.3M | 1.26M | 25.12M | 27.95M | 30.7M | 27.71M | 30.59M | 29.33M | 685.16K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Critical liquidity and clinical binary
As indicated by the company's financial statements, Sensei Biotherapeutics remains a pre-revenue entity, with no recurring income streams to offset its ongoing research expenditures, leaving the firm entirely dependent on external capital markets to fund its clinical development pipeline and general corporate operations moving forward.
The lack of revenue generation is consistent with the company's current stage as a clinical-stage biotechnology firm. Investors should note that the absence of top-line growth underscores the binary nature of the investment, where value is derived solely from clinical trial milestones rather than operational performance.
Based on reported figures, the company maintains a high fixed-cost structure primarily driven by R&D activities, with quarterly research expenses consistently consuming the majority of available capital, which suggests a limited operational runway without immediate access to additional dilutive financing or strategic partnership capital inflows.
The persistent R&D spend reflects the intensive nature of managing the SNS-101 Phase 1/2 clinical trial. This cost structure appears rigid, as the company lacks the scale to absorb these expenses, necessitating a high degree of fiscal discipline to avoid further erosion of the remaining cash position.
According to recent SEC filings, the reported net loss figures are significantly impacted by non-cash items and lumpy clinical trial accruals, which complicates the assessment of the company's underlying burn rate and obscures the true economic cost of its ongoing research and development initiatives.
The presence of stock-based compensation and irregular clinical trial expenses suggests that headline net income figures may not accurately reflect the company's cash-based operational efficiency. Analysts should monitor these adjustments closely to determine the actual rate at which the company is consuming its limited liquidity.
As reported in financial statements, the company's cash position of $8,668,000 creates a precarious liquidity profile, which suggests that the firm may face significant challenges in sustaining its current clinical trial trajectory without an immediate and potentially dilutive capital raise to address its funding gap.
The current cash balance appears insufficient to support long-term clinical development, raising concerns about the company's ability to reach critical data readouts. This liquidity risk warrants further investigation into the potential for a strategic transaction or a restructuring of the current research pipeline to preserve capital.
Quick answers to the most common questions about buying SNSE stock.
For fiscal year 2025, Sensei Biotherapeutics, Inc. (SNSE) reported total revenue of $0.0M.
Sensei Biotherapeutics, Inc. (SNSE) reported a net loss of $21.1M for the fiscal year ending 2025.